Letter: Association of serum growth differentiation factor 15 and liver‐related outcomes in patients with <scp>MASLD</scp>-Reference-Cited by-同舟云学术

Letter: Association of serum growth differentiation factor 15 and liver‐related outcomes in patients with MASLD

Published:2024-07-29 Issue:6 Volume:60 Page:825-826
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Wang Jian¹²,Fan Tao³,Zhang Shaoqiu¹,Wu Chao¹²^ORCID,Huang Rui¹²³^ORCID

Affiliation:

1. Department of Infectious Diseases Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing Jiangsu China

2. Institute of Viruses and Infectious Diseases Nanjing University Nanjing Jiangsu China

3. Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine Nanjing Jiangsu China

Abstract

LINKED CONTENTThis article is linked to Kumazaki et al papers. To view these articles, visit https://doi.org/10.1111/apt.18063 and https://doi.org/10.1111/apt.18186

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18150

Reference5 articles.

1. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis

2. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

3. GDF15 mediates the effects of metformin on body weight and energy balance

4. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin

5. Asian perspective on NAFLD-associated HCC

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter: Association of serum growth differentiation factor 15 and liver‐related outcomes in patients with MASLD—Authors' reply;Alimentary Pharmacology & Therapeutics;2024-07-29